Jay Olson Analyst PerformanceAnalyst at OppenheimerJay Olson is a stock analyst at Oppenheimer focused in the healthcare sector, covering 51 publicly traded companies. Over the past year, Jay Olson has issued 37 stock ratings, including buy and hold recommendations. While full access to Jay Olson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jay Olson's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings317 Last 11 YearsBuy Recommendations80.19% 247 Buy RatingsCompanies Covered51 Unique Companies Ratings Distribution308RatingsDistribution of strong buy, buy, hold, and sell ratings by Jay Olson.RatingPercentageCount Strong Buy0.0%0 ratings Buy80.2%247 ratings Hold18.8%58 ratings Sell1.0%3 ratingsOut of 308 total stock ratings issued by Jay Olson at Oppenheimer, the majority (80.2%) have been Buy recommendations, followed by 18.8% Hold and 1.0% Sell.Best & Worst CallsBest Call0000.0%PRAXJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CNATOct 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ51 companiesJay Olson, an analyst at Oppenheimer, currently covers 51 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare50 companies98.0%Industrials1 company2.0%Jay Olson of Oppenheimer specializes in stock coverage within the Healthcare sector, with additional focus on Industrials companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY38 companies74.5%PHARMACEUTICALS12 companies23.5%AEROSPACE & DEFENSE1 company2.0% Jay Olson's Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRVMDRevolution Medicines8/6/2026Reiterated Rating$200.67$230.00Outperform$0.0000.00% ROIAMGNAmgen8/5/2026Boost Price Target$390.63$450.00Outperform$0.0000.00% ROIBIIBBiogen7/29/2026Reiterated Rating$209.43$300.00Outperform$0.0000.00% ROIINCYIncyte7/28/2026Reiterated Rating$129.80$120.00Market Perform$0.0000.00% ROIFTHSensei Biotherapeutics7/28/2026Initiated Coverage$29.24$60.00Outperform$0.0000.00% ROIQTTBQ32 Bio7/13/2026Boost Price Target$20.31$40.00Outperform$0.0000.00% ROIKYNBKyntra Bio7/6/2026Initiated Coverage$7.25$35.00Outperform$0.0000.00% ROIEPRXEupraxia Pharmaceuticals6/25/2026Initiated Coverage$6.41$17.00Outperform$0.0000.00% ROIDFTXDefinium Therapeutics6/22/2026Set Price Target$37.55$60.00Outperform$0.0000.00% ROIINCYIncyte6/8/2026Reiterated Rating$100.73$107.00Market Perform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. PRAXPraxis Precision Medicines6/2/2026Reiterated Rating$335.16$650.00Outperform$0.0000.00% ROIRVMDRevolution Medicines6/1/2026Boost Price Target$157.48$195.00Outperform$0.0000.00% ROIANLAdlai Nortye5/28/2026Initiated Coverage$11.00$32.00Outperform$0.0000.00% ROIBIIBBiogen5/14/2026Boost Price Target$192.43$300.00Outperform$0.0000.00% ROIINCYIncyte4/29/2026Boost Price Target$97.74$90.00Market Perform$0.0000.00% ROITERNTerns Pharmaceuticals4/27/2026Reiterated Rating$52.91$58.00Market Perform$0.0000.00% ROIPASGPassage Bio4/21/2026Lower Price Target$6.18$15.00Outperform$0.0000.00% ROIBIIBBiogen4/1/2026Boost Price Target$183.33$275.00Outperform$0.0000.00% ROIPASGPassage Bio3/31/2026Initiated Coverage$6.18$30.00Outperform$0.0000.00% ROIBCYCBicycle Therapeutics3/18/2026Lower Price Target$4.83$36.00Outperform$0.0000.00% ROINKTRNektar Therapeutics3/13/2026Reiterated Rating$73.00$140.00Outperform$0.0000.00% ROIVRTXVertex Pharmaceuticals3/10/2026Boost Price Target$460.87$600.00Outperform$0.0000.00% ROIBIOABioAge Labs2/25/2026Initiated Coverage$21.56$60.00Outperform$0.0000.00% ROIVRTXVertex Pharmaceuticals2/13/2026Upgrade$465.02$540.00Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals2/6/2026Boost Price Target$23.79$23.00Market Perform$0.0000.00% ROIBIIBBiogen1/30/2026Boost Price Target$176.18$225.00Outperform$0.0000.00% ROICHRSCoherus Oncology1/22/2026Initiated Coverage$1.59$10.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics12/31/2025Reiterated Rating$183.95$220.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines12/15/2025Reiterated Rating$268.80$750.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals12/9/2025Boost Price Target$40.23$58.00Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/20/2025Boost Price Target$555.60$650.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals11/3/2025Reiterated Rating$14.03$24.00Outperform$0.0000.00% ROIIBIOiBio10/29/2025Reiterated Rating$1.54Outperform$0.0000.00% ROIIBIOiBio10/21/2025Initiated Coverage$0.89$5.00Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals10/10/2025Boost Price Target$428.30$590.00Outperform$0.0000.00% ROIIMRXImmuneering9/25/2025Boost Price Target$8.36$30.00Outperform$0.0000.00% ROIBCYCBicycle Therapeutics8/11/2025Reiterated Rating$7.59$44.00Outperform$0.0000.00% ROIDFTXDefinium Therapeutics8/4/2025Initiated Coverage$8.44$25.00Outperform$00.0000.00% ROIATAIAtai Beckley7/29/2025Initiated Coverage$3.33$14.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines7/8/2025Boost Price Target$46.39$115.00Outperform$000.0000.00% ROIThe $15 Gold Fund That Pays Up to $1,152/Month (Ad)Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.Discover the gold income fund before the next payout datePRAXPraxis Precision Medicines6/2/2025Set Price Target$37.82$97.00Outperform$000.0000.00% ROIPRTAProthena5/27/2025Downgrade$6.58Market Perform$00.0000.00% ROITVRDTvardi Therapeutics5/21/2025Initiated Coverage$29.09$65.00Outperform$0.0000.00% ROIJSPRJasper Therapeutics5/15/2025Lower Price Target$4.88$65.00Outperform$0.0000.00% ROIINOInovio Pharmaceuticals5/14/2025Lower Price Target$1.86$13.00Outperform$0.0000.00% ROIRVMDRevolution Medicines5/8/2025Boost Price Target$42.56$75.00Outperform$000.0000.00% ROIIMRXImmuneering5/7/2025Lower Price Target$1.18$21.00Outperform$0.0000.00% ROIBIIBBiogen5/2/2025Set Price Target$121.80$205.00$000.0000.00% ROINKTRNektar Therapeutics3/14/2025Upgrade$12.23$90.00Outperform$00.0000.00% ROIDNLIDenali Therapeutics3/3/2025Lower Price Target$15.46$42.00Outperform$00.0000.00% ROIPRTAProthena2/7/2025Boost Price Target$13.93$62.00Outperform$0.0000.00% ROIEXELExelixis1/24/2025Downgrade$34.13$33.00Market Perform$00.0000.00% ROIEXELExelixis1/16/2025Boost Price Target$36.81$41.00Outperform$00.0000.00% ROINTLAIntellia Therapeutics1/13/2025Lower Price Target$9.99$40.00Outperform$00.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock10/17/2024Boost Price Target$6.71$10.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
